Animal models demonstrated an increase in SPP1-expressing macrophages, associated with lung fibrosis, while blocking SPP1 reduced mortality and inflammation, indicating its potential as a therapeutic target [83]. This evidence concerns the gene SPP1 and pulmonary fibrosis.